The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial

We examined the effects of a dihydropyridine calcium channel blocker nilvadipine with anti-inflammatory properties on cognition and cerebrospinal fluid (CSF) biomarkers by baseline Alzheimer's disease (AD) severity. Exploratory analyses were performed on the dataset (n = 497) of a phase III ran...

Full description

Bibliographic Details
Main Authors:	Laila Abdullah, Fiona Crawford, Magda Tsolaki, Anne Börjesson-Hanson, Marcel Olde Rikkert, Florence Pasquier, Anders Wallin, Sean Kennelly, Ghania Ait-Ghezala, Daniel Paris, Suzanne Hendrix, Kaj Blennow, Brian Lawlor, Michael Mullan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-03-01
Series:	Frontiers in Neurology
Subjects:	mild Alzheimer's disease nilvadipine exploratory analysis cognitive decline cerebrospinal fluid Aβ42/Aβ40 ratios
Online Access:	https://www.frontiersin.org/article/10.3389/fneur.2020.00149/full

Similar Items

Ophthalmic Formulation Containing Nilvadipine Nanoparticles Prevents Retinal Dysfunction in Rats Injected with Streptozotocin
by: Saori Deguchi, et al.
Published: (2017-12-01)

Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
by: Jonas Elias Schweig, et al.
Published: (2017-09-01)

Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: data from NILVAD
by: Adam H. Dyer, et al.
Published: (2020-03-01)

Proteomic Identification of Pathways Responsible for the Estradiol Therapeutic Window in AD Animal Models
by: Jie Cui, et al.
Published: (2019-10-01)

Repeated lumbar punctures within 3 days may affect CSF biomarker levels
by: Martin Olsson, et al.
Published: (2019-12-01)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
by: François Mouton-Liger, et al.
Published: (2020-07-01)

Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link
by: Jaime Ramos-Cejudo, et al.
Published: (2018-02-01)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
by: Nicholas J. Ashton, et al.
Published: (2019-12-01)

Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease
by: Linda Helmfors, et al.
Published: (2015-11-01)

Amelioration of experimental autoimmune encephalomyelitis by anatabine.
by: Daniel Paris, et al.
Published: (2013-01-01)

CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology
by: J. S. Miners, et al.
Published: (2019-09-01)

Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation
by: Jill A. White, et al.
Published: (2005-04-01)

Correction: Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.
by: Megha Verma, et al.
Published: (2015-01-01)

Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.
by: Megha Verma, et al.
Published: (2015-01-01)

Oxygenated Analogues of Santacruzamate A
by: Plamen Angelov, et al.
Published: (2021-02-01)

Common Variants in PLXNA4 and Correlation to CSF-related Phenotypes in Alzheimer's Disease
by: Qiu Han, et al.
Published: (2018-12-01)

The past and the future of Alzheimer’s disease CSF biomarkers – a journey towards validated biochemical tests covering the whole spectra of molecular events
by: Kaj eBlennow
Published: (2015-09-01)

Synergistic Effect on Neurodegeneration by N-Truncated Aβ4−42 and Pyroglutamate Aβ3−42 in a Mouse Model of Alzheimer's Disease
by: Jose S. Lopez-Noguerola, et al.
Published: (2018-03-01)

The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor
by: Kumju Youn, et al.
Published: (2016-10-01)

A fast, miniaturised in-vitro assay developed for quantification of lipase enzyme activity
by: Ariane Menden, et al.
Published: (2019-01-01)

Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid
by: Cheryl A. Luis, et al.
Published: (2011-01-01)

Impacts of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in alzheimer’s disease
by: Xi-chen Zhu, et al.
Published: (2020-09-01)

The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals
by: Davide Bruno, et al.
Published: (2015-03-01)

SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)
by: Laurent Pradier, et al.
Published: (2018-11-01)

Cerebrospinal fluid Aβ40 improves the interpretation of Aβ42 concentration for diagnosing Alzheimer’s disease.
by: Aline eDorey, et al.
Published: (2015-11-01)

Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterization
by: Timothy M. Ryan, et al.
Published: (2013-05-01)

Extracellular Vesicles in Alzheimer’s Disease: Friends or Foes? Focus on Aβ-Vesicle Interaction
by: Pooja Joshi, et al.
Published: (2015-03-01)

Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid β precursor protein
by: Lorena Heredia, et al.
Published: (2004-08-01)

BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time
by: Yi Luo, et al.
Published: (2003-10-01)

Anti-Parallel β-Hairpin Structure in Soluble Aβ Oligomers of Aβ40-Dutch and Aβ40-Iowa
by: Ziao Fu, et al.
Published: (2021-01-01)

Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
by: Lieke Jäkel, et al.
Published: (2019-09-01)

Removal of blood amyloid-β with hemodialysis reduced brain amyloid-β, confirmed by brain imaging: a case report
by: Kitaguchi N, et al.
Published: (2018-11-01)

The role of N-truncated Aβ peptides in Alzheimer’s Disease
by: Lopez Noguerola, Jose Socrates
Published: (2018)

Adaptive Immune Responses Associated with the Central Nervous System Pathology of Gulf War Illness
by: Aurore Nkiliza, et al.
Published: (2021-05-01)

Oligomeric and Fibrillar Species of Aβ42 Diversely Affect Human Neural Stem Cells
by: Adela Bernabeu-Zornoza, et al.
Published: (2021-09-01)

Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels
by: Javier Pacheco-Quinto, et al.
Published: (2006-06-01)

Induction of amyloid-β deposits from serially transmitted, histologically silent, Aβ seeds issued from human brains
by: Anne-Sophie Hérard, et al.
Published: (2020-11-01)

9-Methylfascaplysin Is a More Potent Aβ Aggregation Inhibitor than the Marine-Derived Alkaloid, Fascaplysin, and Produces Nanomolar Neuroprotective Effects in SH-SY5Y Cells
by: Qingmei Sun, et al.
Published: (2019-02-01)

β-Glucosidase and β-Galactosidase-Mediated Transglycosylation of Steviol Glycosides Utilizing Industrial Byproducts
by: Anastasia Zerva, et al.
Published: (2021-06-01)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ42/40 ratio
by: Hélène Pouclet‐Courtemanche, et al.
Published: (2019-12-01)

Cannot write session to /tmp/vufind_sessions/sess_8324aisq5fg5ho43cg2jc9rj1d